Project Grant R01CA285737
Award Date
6/6/24
Completion Date
5/31/29
Dollars Obligated
$710K
Federal Agency
National Cancer Institute
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Yale University totals $167,500 and will be executed from September 2023 through August 2025. The primary objectives are to: Develop deep neural network-based emulation analysis methods and software to objectively quantify the relative effectiveness of drugs, devices, and treatment procedures on cancer prognosis, especially when randomized clinical trials are not feasible. The...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will provide $161,000 to the University of Connecticut to conduct a pilot study on communication about sexuality and intimacy between individuals with metastatic breast cancer (MBC) and their partners. The study aims to: 1) identify themes in MBC patients' communication about sexuality and intimacy, 2) determine if specific communication features are...
The National Cancer Institute (NCI) awarded a $182,236 Project Grant (CFDA 93.398 - Cancer Research Manpower) to New York University (NYU) School of Medicine to adapt and pilot test an evidence-based sexual health communication skills training intervention for prostate cancer patients. The project aims to address gaps in patient-provider communication about sexual dysfunction, a common side effect of prostate cancer treatment that significantly impacts quality of life. Key activities include...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $257,413 to Dartmouth-Hitchcock Clinic, a non-profit healthcare provider, to develop and test an interactive visual aid for approaching decision-making around stopping cancer treatment in patients with advanced cancer. The key objectives are to: 1) assess patient-caregiver-clinician shared understanding following serious illness conversations, 2) develop and refine a highly...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $459,867 to Brigham & Women's Hospital Inc. over the period of September 1, 2024 to August 31, 2029. The objective is to develop and validate natural language processing (NLP) methods, particularly using neural language models, to extract and monitor immune-related adverse events (IRAEs) from electronic health records (EHRs) for cancer patients treated with immune...
The National Cancer Institute (NCI) awarded a $762,258 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to Cedars-Sinai Medical Center in California to develop a natural language processing (NLP) and artificial intelligence (AI)-based feedback system for improving patient decision-making and physician risk communication in prostate cancer treatment. The project aims to test whether providing NLP-based feedback summarizing key treatment tradeoffs to patients and physicians after...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $442,089 to Yale University to conduct research on the regulatory pathways affected by inhibition of the enzyme PRMT5 in cancer cells with MTAP loss. The project aims to identify key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and define pathways that can restore viability. Specifically, the research will examine the impact of...
The National Cancer Institute awarded a $388,800 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to HMH Hospitals Corporation's Hackensack University Medical Center. This 9-month grant, effective July 1, 2024, will fund a multilevel intervention to address communication barriers around complementary and alternative therapies (CAM) among cancer patients. The intervention will provide cancer patients with a CAM question prompt list to facilitate open discussions with their...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $212,567 in funding to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to support the awardee's role as a laboratory-based research specialist and director of the Computational Immunogenomics Platform (IGP). The primary focus is on computational analysis of cancer patient-derived next-generation sequencing data to advance the field of immunogenomics...
This federal Project Grant award, valued at $398,207.00 and provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), aims to develop and test a multilevel intervention to improve interdisciplinary communication quality in low-resource pediatric oncology hospitals. The key products and services to be delivered under this five-year grant include: Conducting a cross-sectional social network analysis across 20 hospitals to identify the relationship between...